Results 21 to 30 of about 5,368 (169)

The development of potential targets in the treatment of non-small cell lung cancer

Open Life Sciences, 2016
The oncogenic driver mutations have been found that not only have potential sensitivity to epidermal growth factor receptor but also can inhibit anaplastic lymphoma kinase tyrosine kinase; more and more interest has been evoked in discovering additional ...
Zhang Jimin, Lin Zhihui
doaj   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician

Radiology and Oncology, 2019
Colorectal cancer is a successful model of genetic biomarker development in oncology. Currently, several predictive or prognostic genetic alterations have been identified and are used in clinical practice.
Afrăsânie Vlad-Adrian, Marinca Mihai Vasile, Alexa-Stratulat Teodora, Gafton Bogdan, Păduraru Marius, Adavidoaiei Anca Maria, Miron Lucian, Rusu Cristina   +7 more
doaj   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Targeting BRAF in cancers – from molecular diagnostics to personalized therapy

BioTechnologia
Molecular profiling has become a cornerstone of cancer diagnosis and treatment, with BRAF alterations serving as significant markers across various tumor types.
Zuzanna Pyc, Rafal Rygiel, Dagmara Michalowska, Marcin Ekiert, Izabela Laczmanska   +4 more
doaj   +1 more source

Serrated lesions of the colon and rectum: Emergent epidemiological data and molecular pathways

Open Medicine, 2020
In 2010, serrated polyps (SP) of the colon have been included in the WHO classification of digestive tumors. Since then a large corpus of evidence focusing on these lesions are available in the literature.
Sacco Michele, De Palma Fatima Domenica Elisa, Guadagno Elia, Giglio Mariano Cesare, Peltrini Roberto, Marra Ester, Manfreda Andrea, Amendola Alfonso, Cassese Gianluca, Dinuzzi Vincenza Paola, Pegoraro Francesca, Tropeano Francesca Paola, Luglio Gaetano, De Palma Giovanni Domenico   +13 more
doaj   +1 more source

Targeted Therapy in the Management of Modern Craniopharyngiomas

Frontiers in Bioscience-Landmark, 2022
Background: The proximity of craniopharyngiomas (CPs) to critical neurovascular structures can lead to a host of neurologic and endocrine complications that lead to difficulty with surgical management. In this review, we examine the molecular and genetic
Maikerly Reyes, Mohammad Taghvaei, Siyuan Yu, Anish Sathe, Sarah Collopy, Giyarpuram N. Prashant, James J. Evans, Michael Karsy   +7 more
doaj   +1 more source

Comparative study between Immunohistochemistry and Molecular method in detection of BRAF V600E mutation in papillary thyroid carcinoma

Basrah Journal of Surgery, 2023
Background Papillary thyroid carcinoma is the most common endocrine and thyroid malignancy. The (BRAF V600E) mutation is the most common mutation in papillary thyroid cancer (PTC). The mutation is detected in about (60%) of the cases.
Sarah Ali Darweesh, Jasim M. Al-Diab, Sawsan S. Al-Harron, Hussam Aziz Hasson   +3 more
doaj   +1 more source

European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender

BJS (British Journal of Surgery), EarlyView., 2020
Recommendations for clinical and molecular identification of LS, surgical and endoscopic management of LS‐associated colorectal cancer and preventive measures for cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer spectrum.
T. T. Seppälä, A. Latchford, I. Negoi, A. Sampaio Soares, R. Jimenez‐Rodriguez, L. Sánchez‐Guillén, D. G. Evans, N. Ryan, E. J. Crosbie, M. Dominguez‐Valentin, J. Burn, M. Kloor, M. von Knebel Doeberitz, F. J. B. van Duijnhoven, P. Quirke, J. R. Sampson, P. Møller, G. Möslein, on behalf of the European Hereditary Tumour Group (EHTG) and European Society of Coloproctology (ESCP)   +18 more
wiley   +1 more source

GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA

Сибирский онкологический журнал, 2020
Objective: to detect new molecular genetic markers and therapeutic targets in retroperitoneal myxoid liposarcoma.Material and Methods. DNA samples isolated from tumor tissue and obtained from formalinfixed paraffin-embedded (FFPE) slides were used.
A. Yu. Volkov, V. M. Safronova, S. N. Nered, L. N. Lyubchenko, I. S. Stilidi   +4 more
doaj   +1 more source